Physician profile
Patricia Adriana Ares-Romero
NPI 1902823719
$507,884.01
in general payments reported to CMS, 2019-2025
22 companies · $177K in 2025
The $177K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $20K · 2021: $19K · 2022: $108K · 2023: $46K · 2024: $77K · 2025: $177K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $194K · Consulting Fee: $51K · Travel and Lodging: $44K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,173.00 |
| Consulting Fee | $50,899.50 |
| Travel and Lodging | $44,067.53 |
| Food and Beverage | $10,350.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $164,120.73 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $137,652.82 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $60,920.24 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53,761.40 | 2021-2025 | Caplyta |
| Alkermes, INC. | $42,302.11 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $38,310.10 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $4,428.11 | 2019-2022 | |
| Sandoz INC. | $3,971.25 | 2019 | |
| Pear Therapeutics (US), INC. | $496.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $283.08 | 2019-2021 | |
| Neuronetics, INC. | $273.66 | 2020 | |
| Abbvie INC. | $209.91 | 2021-2024 | Vraylar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $183.13 | 2021-2024 | Rejoyn |
| Livanova USA, INC. | $176.82 | 2021 | |
| Boston Scientific Corporation | $155.76 | 2025 | Watchman Flx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $139.98 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $123.89 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $120.24 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $88.69 | 2023 | |
| Lundbeck LLC | $76.23 | 2021-2022 | |
| Biogen, INC. | $71.32 | 2025 | Zurzuvae |
| Brainsway USA INC | $17.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Ares-Romero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.